Doxycycline decreases proteinuria in glomerulonephritis

American Journal of Kidney Diseases

Volumn 42, Issue 2, 2003, Pages 376-380

  Ahuja, Tejinder S ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b 4200 John Sealy Annex ^*  (United States)

Author keywords

Antineutrophil cytoplasmic antibody; Crescentic glomerulonephritis; Doxycycline; Glomerulonephritis; Metalloproteinase inhibitors; Metalloproteinases; Proteinuria; Tetracycline; Vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXYCYCLINE; PREDNISOLONE;

ACNE; ADULT; ANAMNESIS; ARTICLE; BIOPSY; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MEDICAL EXAMINATION; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SMALL VESSEL VASCULITIS;

EID: 0041625966     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00662-0     Document Type: Article

References (25)

1. Jennette CJ: Rapidly progressive glomerulonephritis. Kidney Int 63:1164-1177, 2003
2. Lenz O, Elliot SJ, Steller-Stevenson WG: Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 11:574-581, 2000
3. Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47:481-489, 1995
4. Lovett DH, Johnson RJ, Marti HP, Martin J, Davies M, Couser WG: Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol 141:85-98, 1992
5. Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti-Thy 1.1 nephritis. J Am Soc Nephrol 9:397-407, 1998
6. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH: Characterization of a glomerular epithelial cell metalloproteinase as a matrix metalloproteinase-9 with enhanced expression in a model of membranous glomerulonephritis. J Clin Invest 97:1094-1101, 1996
7. Hayashi K, Horikoshi S, Osada S, et al: Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis. J Pathol 191:299-305, 2000
8. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T: Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv Dent Res 12:12-26, 1998
9. Novak MJ, Johns LP, Miller RC, Bradshaw MH: Adjunctive benefits of subantimicrobial dose of doxycycline in the management of severe, generalized, chronic periodontitis. J Periodontol 73:762-769, 2002
10. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD: Specificity of inhibition of matrix metalloproteinase activity by doxycycline: Relationship to structure of the enzyme. Arthritis Rheum 42:1140-1146, 1999
11. Fife RS, Rougraff BT, Proctor C, Sledge GW Jr: Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med 130:530-534, 1997
12. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, et al: The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase mechanism. Cancer Chemother Pharmacol 36:418-424, 1995
13. Fife RS, Sledge GW Jr, Roth BJ, Proctor C: Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 125:407-411, 1995
14. Baxter BT, Pearce WH, Waltke EA, et al: Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective multicenter study. J Vasc Surg 36:1-12, 2002
15. Schwab SJ, Christensen RL, Dougherty K, Klahr S: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 147:943-944, 1987
16. Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 309:1543-1546, 1983
17. Massova I, Kotra LP, Fridman R, Mobashery S: Matrix metalloproteinases: Structure, evolution and diversification. FASEB J 12:1075-1095, 1998
18. Koide H, Nakamura T, Ebihara I, Tomino Y: Increased mRNA expression of metalloproteinase-9 in peripheral-blood monocytes from patients with immunoglobulin A nephropathy. Am J Kidney Dis 28:32-39, 1996
19. Akiyama K, Shikata K, Sugimoto H, et al: Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 95:115-128, 1997
20. Nagase H: Activation mechanism of matrix metalloproteinases. Biol Chem 378:151-160, 1997
21. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C: Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 56:944-949, 1996
22. Takino T, Sato H, Yamamoto E, Seiki M: Cloning of a human gene potentially encoding a novel matrix metalloproteinase has a C-terminal transmembrane domain. Gene 155:293-298, 1995
23. Sato H, Takino T, Okada Y, et al: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370:61-65, 1994
24. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387-2391, 2002
25. Denis LJ, Verweij J: Matrix metalloproteinase inhibitors: Present achievements and future prospects. Invest New Drugs 15:175-85, 1997